The lipid peroxidation metabolite 4-oxo-2-nonenal cross-links α-synuclein causing rapid formation of stable oligomers

Biochemical and Biophysical Research Communications

Volumn 378, Issue 4, 2009, Pages 872-876

  Näsström, Tomas ^a   Wahlberg, Therese ^a   Karlsson, Mikael ^b   Nikolajeff, Fredrik ^b   Lannfelt, Lars ^a   Ingelsson, Martin ^a   Bergström, Joakim ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

Synuclein; 4 Oxo 2 nonenal; Dementia with Lewy bodies; Oligomers; Oxidative stress; Parkinson's disease

Indexed keywords

4 OXO 2 NONENAL; ALDEHYDE; ALPHA SYNUCLEIN; DODECYL SULFATE SODIUM; OLIGOMER; UNCLASSIFIED DRUG;

ARTICLE; BETA SHEET; CROSS LINKING; DEMENTIA; IN VITRO STUDY; INCUBATION TIME; LEWY BODY; LIPID PEROXIDATION; METABOLITE; NERVE DEGENERATION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN STABILITY; STRUCTURE ANALYSIS;

ALDEHYDES; ALPHA-SYNUCLEIN; AMYLOID; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; LIPID PEROXIDATION; MICROSCOPY, ATOMIC FORCE; MOLECULAR WEIGHT; PARKINSONIAN DISORDERS; PROTEIN CONFORMATION; SODIUM DODECYL SULFATE;

EID: 58049202748     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.005     Document Type: Article

References (29)

1. Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., and Goedert M. Alpha-synuclein in Lewy bodies. Nature 388 (1997) 839-840
2. Zarranz J.J., Alegre J., Gomez-Esteban J.C., Lezcano E., Ros R., Ampuero I., Vidal L., Hoenicka J., Rodriguez O., Atares B., Llorens V., Gomez Tortosa E., del Ser T., Munoz D.G., and de Yebenes J.G. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann. Neurol. 55 (2004) 164-173
3. Singleton A.B., Farrer M., Johnson J., Singleton A., Hague S., Kachergus J., Hulihan M., Peuralinna T., Dutra A., Nussbaum R., Lincoln S., Crawley A., Hanson M., Maraganore D., Adler C., Cookson M.R., Muenter M., Baptista M., Miller D., Blancato J., Hardy J., and Gwinn-Hardy K. Alpha-synuclein locus triplication causes Parkinson's disease. Science 302 (2003) 841
4. Polymeropoulos M.H., Lavedan C., Leroy E., Ide S.E., Dehejia A., Dutra A., Pike B., Root H., Rubenstein J., Boyer R., Stenroos E.S., Chandrasekharappa S., Athanassiadou A., Papapetropoulos T., Johnson W.G., Lazzarini A.M., Duvoisin R.C., Di Iorio G., Golbe L.I., and Nussbaum R.L. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997) 2045-2047
5. Kruger R., Kuhn W., Muller T., Woitalla D., Graeber M., Kosel S., Przuntek H., Epplen J.T., Schols L., and Riess O. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat. Genet. 18 (1998) 106-108
6. Outeiro T.F., Putcha P., Tetzlaff J.E., Spoelgen R., Koker M., Carvalho F., Hyman B.T., and McLean P.J. Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS ONE 3 (2008) e1867
7. Danzer K.M., Haasen D., Karow A.R., Moussaud S., Habeck M., Giese A., Kretzschmar H., Hengerer B., and Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J. Neurosci. 27 (2007) 9220-9232
8. Uversky V.N., Gillespie J.R., and Fink A.L. Why are "natively unfolded" proteins unstructured under physiologic conditions?. Proteins 41 (2000) 415-427
9. Davidson W.S., Jonas A., Clayton D.F., and George J.M. Stabilization of alpha-synuclein secondary structure upon binding to synthetic membranes. J. Biol. Chem. 273 (1998) 9443-9449
10. Liu S., Ninan I., Antonova I., Battaglia F., Trinchese F., Narasanna A., Kolodilov N., Dauer W., Hawkins R.D., and Arancio O. Alpha-synuclein produces a long-lasting increase in neurotransmitter release. EMBO J. 23 (2004) 4506-4516
11. Clayton D.F., and George J.M. Synucleins in synaptic plasticity and neurodegenerative disorders. J. Neurosci. Res. 58 (1999) 120-129
12. Uversky V.N., Li J., Souillac P., Millett I.S., Doniach S., Jakes R., Goedert M., and Fink A.L. Biophysical properties of the synucleins and their propensities to fibrillate: inhibition of alpha-synuclein assembly by beta- and gamma-synucleins. J. Biol. Chem. 277 (2002) 11970-11978
13. Castellani R.J., Perry G., Siedlak S.L., Nunomura A., Shimohama S., Zhang J., Montine T., Sayre L.M., and Smith M.A. Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci. Lett. 319 (2002) 25-28
14. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
15. Gaeta A., and Hider R.C. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br. J. Pharmacol. 146 (2005) 1041-1059
16. Esterbauer H., Schaur R.J., and Zollner H. Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic. Biol. Med. 11 (1991) 81-128
17. Schneider C., Tallman K.A., Porter N.A., and Brash A.R. Two distinct pathways of formation of 4-hydroxynonenal. Mechanisms of nonenzymatic transformation of the 9- and 13-hydroperoxides of linoleic acid to 4-hydroxyalkenals. J. Biol. Chem. 276 (2001) 20831-20838
18. Lin D., Lee H.G., Liu Q., Perry G., Smith M.A., and Sayre L.M. 4-Oxo-2-nonenal is both more neurotoxic and more protein reactive than 4-hydroxy-2-nonenal. Chem. Res. Toxicol. 18 (2005) 1219-1231
19. Stewart B.J., Doorn J.A., and Petersen D.R. Residue-specific adduction of tubulin by 4-hydroxynonenal and 4-oxononenal causes cross-linking and inhibits polymerization. Chem. Res. Toxicol. 20 (2007) 1111-1119
20. Qin Z., Hu D., Han S., Reaney S.H., Di Monte D.A., and Fink A.L. Effect of 4-hydroxy-2-nonenal modification on alpha-synuclein aggregation. J. Biol. Chem. 282 (2007) 5862-5870
21. Nieva J., Shafton A., Altobell III L.J., Tripuraneni S., Rogel J.K., Wentworth A.D., Lerner R.A., and Wentworth Jr. P. Lipid-derived aldehydes accelerate light chain amyloid and amorphous aggregation. Biochemistry 47 (2008) 7695-7705
22. Siegel S.J., Bieschke J., Powers E.T., and Kelly J.W. The oxidative stress metabolite 4-hydroxynonenal promotes Alzheimer protofibril formation. Biochemistry 46 (2007) 1503-1510
23. Rindgen D., Nakajima M., Wehrli S., Xu K., and Blair I.A. Covalent modifications to 2′-deoxyguanosine by 4-oxo-2-nonenal, a novel product of lipid peroxidation. Chem. Res. Toxicol. 12 (1999) 1195-1204
24. Zhang W.H., Liu J., Xu G., Yuan Q., and Sayre L.M. Model studies on protein side chain modification by 4-oxo-2-nonenal. Chem. Res. Toxicol. 16 (2003) 512-523
25. Yoritaka A., Hattori N., Uchida K., Tanaka M., Stadtman E.R., and Mizuno Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc. Natl. Acad. Sci. USA 93 (1996) 2696-2701
26. Lee S.H., Rindgen D., Bible Jr. R.H., Hajdu E., and Blair I.A. Characterization of 2′-deoxyadenosine adducts derived from 4-oxo-2-nonenal, a novel product of lipid peroxidation. Chem. Res. Toxicol. 13 (2000) 565-574
27. Doorn J.A., and Petersen D.R. Covalent adduction of nucleophilic amino acids by 4-hydroxynonenal and 4-oxononenal. Chem. Biol. Interact. 143-144 (2003) 93-100
28. Doorn J.A., and Petersen D.R. Covalent modification of amino acid nucleophiles by the lipid peroxidation products 4-hydroxy-2-nonenal and 4-oxo-2-nonenal. Chem. Res. Toxicol. 15 (2002) 1445-1450
29. Ehrnhoefer D.E., Bieschke J., Boeddrich A., Herbst M., Masino L., Lurz R., Engemann S., Pastore A., and Wanker E.E. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers. Nat. Struct. Mol. Biol. 15 (2008) 558-566